Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019

Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019

Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019

Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019

Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2019

Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2018

Same journal

Formulary Substitution of Proton Pump Inhibitors Based on Acquisition Price: Changes in Usage and Costs of Acid-Suppressant Therapies.

P & T : a peer-reviewed journal for formulary management·2021

Same journal

Is Ciprofloxacin in Combination With Beta-lactam Antibiotics a Recipe for Thrombocytosis?: A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone.

P & T : a peer-reviewed journal for formulary management·2021

Same journal

Looking for Trouble: Identifying and Treating Hypotension.

P & T : a peer-reviewed journal for formulary management·2019

Same journal

Research Briefs.

P & T : a peer-reviewed journal for formulary management·2019

Same journal

The Impact of Self-Monitoring Blood Glucose Adherence On Glycemic Goal Attainment in an Indigent Population, With Pharmacy Assistance.

P & T : a peer-reviewed journal for formulary management·2019

Same journal

Continuous Glucose Monitoring: A Review of Available Systems.

P & T : a peer-reviewed journal for formulary management·2019

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 8, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Pharmaceutical Approval Update.

Michele B Kaufman

P & T : a Peer-Reviewed Journal for Formulary Management

|February 7, 2017

Summary

This summary is machine-generated.

Three novel therapies offer new hope for common conditions. Prasterone addresses menopausal dyspareunia, crisaborole treats atopic dermatitis, and tenofovir alafenamide manages chronic hepatitis B virus infection.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Mar 8, 2026

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Area of Science:

Pharmacology and Therapeutics
Dermatology
Hepatology

Background:

Dyspareunia due to menopause significantly impacts quality of life.
Atopic dermatitis (eczema) is a chronic inflammatory skin condition.
Chronic hepatitis B virus (HBV) infection poses a global health challenge.

Purpose of the Study:

To review the efficacy and safety of prasterone (Intrarosa) for menopausal dyspareunia.
To evaluate crisaborole (Eucrisa) as a topical treatment for atopic dermatitis.
To assess tenofovir alafenamide (Vemlidy) for the management of chronic hepatitis B.

Main Methods:

Clinical trial data review for prasterone.
Analysis of clinical studies on topical crisaborole.
Examination of outcomes from trials using tenofovir alafenamide.

Main Results:

Prasterone demonstrated improvements in dyspareunia symptoms.
Crisaborole showed efficacy in reducing inflammation and itch in atopic dermatitis.
Tenofovir alafenamide provided effective viral suppression in chronic HBV patients.

Conclusions:

Prasterone offers a new option for treating dyspareunia associated with menopause.
Crisaborole presents a valuable non-steroidal topical treatment for atopic dermatitis.
Tenofovir alafenamide is an effective daily treatment for chronic hepatitis B infection.